Anordiol

Anordiol is a steroid that was developed for medical use but was never marketed. It is a synthetic androgen and anabolic steroid (AAS) and a derivative of testosterone. Anordiol is also known as 2α,17α-diethyl-5α-androstane-3β,17β-diol.

Chemical Structure

Anordiol is a synthetic androgen and anabolic steroid (AAS) and a derivative of testosterone. It is more specifically a derivative of ethisterone (17α-ethynyltestosterone), with the ethynyl group replaced by an ethyl group and the hydroxyl group at the C3 position replaced by a hydrogen atom.

Pharmacology

Pharmacodynamics

As an AAS, anordiol is an agonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT). It has strong anabolic effects and weak androgenic effects, which give it a mild side effect profile and make it especially suitable for use in women.

Pharmacokinetics

The pharmacokinetics of anordiol have not been studied in detail.

History

Anordiol was first described in the literature in 1961. It was developed for medical use by Roussel Uclaf in the 1960s but was never marketed.

Society and Culture

Generic Names

Anordiol is the generic name of the drug and its INN and USAN.

See Also

• List of androgens/anabolic steroids

References

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian